{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35967033", "DateRevised": {"Year": "2022", "Month": "08", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "07", "Day": "27"}], "Language": ["eng"], "ELocationID": ["10.1021/acsomega.2c02835"], "Journal": {"ISSN": "2470-1343", "JournalIssue": {"Volume": "7", "Issue": "31", "PubDate": {"Year": "2022", "Month": "Aug", "Day": "09"}}, "Title": "ACS omega", "ISOAbbreviation": "ACS Omega"}, "ArticleTitle": "Practical and Highly Efficient Synthesis of Remdesivir from GS-441524.", "Pagination": {"StartPage": "27516", "EndPage": "27522", "MedlinePgn": "27516-27522"}, "Abstract": {"AbstractText": ["A three-step sequence for preparing remdesivir, an important anti-SARS-CoV-2 drug, is described. Employing <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (DMF-DMA) as a protecting agent, this synthesis started from (2<i>R</i>,3<i>R</i>,4<i>S</i>,5<i>R</i>)-2-(4-aminopyrrolo[2,1-<i>f</i>][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-furan-2-carbonitrile (GS-441524) and consisted of three reactions, including protection, phosphoramidation, and deprotection. The advantages of this approach are as follows: (1) the protecting group could be removed under a mild deprotection condition, which avoided the generation of the degraded impurity; (2) high stereoselectivity was achieved in the phosphorylated reaction; (3) this synthesis could be performed successively without purification of intermediates. Moreover, the overall yield of this approach on a gram scale could be up to 85% with an excellent purity of 99.4% analyzed by high-performance liquid chromatography (HPLC)."], "CopyrightInformation": "\u00a9 2022 The Authors. Published by American Chemical Society."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, P. R. China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China."}], "LastName": "Hu", "ForeName": "Tianwen", "Initials": "T"}, {"Identifier": ["0000-0001-9075-6474"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Topharman Shanghai Co., Ltd., No.388 Jialilue Road, Zhangjiang Hitech Park, Shanghai 201203 P.R. China."}], "LastName": "Zhu", "ForeName": "Fuqiang", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China."}, {"Identifier": [], "Affiliation": "Nanjing University of Chinese Medicine, Xianlin Road, Nanjing 210023, P. R. China."}], "LastName": "Xiang", "ForeName": "Li", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China."}], "LastName": "Shen", "ForeName": "Jingshan", "Initials": "J"}, {"Identifier": ["0000-0001-9875-887X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lingang Laboratory, Shanghai 200031, P. R. China."}], "LastName": "Xie", "ForeName": "Yuanchao", "Initials": "Y"}, {"Identifier": ["0000-0003-4652-6879"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, P. R. China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China."}], "LastName": "Aisa", "ForeName": "Haji A", "Initials": "HA"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "ACS Omega", "NlmUniqueID": "101691658", "ISSNLinking": "2470-1343"}, "CoiStatement": "The authors declare no competing financial interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Yin W.; Mao C.; Luan X.; Shen D. D.; Shen Q.; Su H.; Wang X.; Zhou F.; Zhao W.; Gao M.; Chang S.; Xie Y. C.; Tian G.; Jiang H. W.; Tao S. C.; Shen J.; Jiang Y.; Jiang H.; Xu Y.; Zhang S.; Zhang Y.; Xu H. E. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020, 368, 1499\u20131504. 10.1126/science.abc1560.", "ArticleIdList": ["10.1126/science.abc1560", "PMC7199908", "32358203"]}, {"Citation": "Gordon C. J.; Tchesnokov E. P.; Woolner E.; Perry J. K.; Feng J. Y.; Porter D. P.; Gotte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020, 295, 6785\u20136797. 10.1074/jbc.RA120.013679.", "ArticleIdList": ["10.1074/jbc.RA120.013679", "PMC7242698", "32284326"]}, {"Citation": "Shannon A.; Le N. T.; Selisko B.; Eydoux C.; Alvarez K.; Guillemot J. C.; Decroly E.; Peersen O.; Ferron F.; Canard B. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020, 178, 104793.10.1016/j.antiviral.2020.104793.", "ArticleIdList": ["10.1016/j.antiviral.2020.104793", "PMC7151495", "32283108"]}, {"Citation": "Wakchaure P. D.; Ghosh S.; Ganguly B. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study. J. Phys. Chem. B 2020, 124, 10641\u201310652. 10.1021/acs.jpcb.0c06747.", "ArticleIdList": ["10.1021/acs.jpcb.0c06747", "33190493"]}, {"Citation": "Wang Y.; Zhang D.; Du G.; Du R.; Zhao J.; Jin Y.; Fu S.; Gao L.; Cheng Z.; Lu Q. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020, 395, 1569\u20131578. 10.1016/S0140-6736(20)31022-9.", "ArticleIdList": ["10.1016/S0140-6736(20)31022-9", "PMC7190303", "32423584"]}, {"Citation": "Goldman J. D.; Lye D. C. B.; Hui D. S.; Marks K. M.; Bruno R.; Montejano R.; Spinner C. D.; Galli M.; Ahn M. Y.; Nahass R. G.; et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N. Engl. J. Med. 2020, 383, 1827\u20131837. 10.1056/NEJMoa2015301.", "ArticleIdList": ["10.1056/NEJMoa2015301", "PMC7377062", "32459919"]}, {"Citation": "FDA\u2019s approval of Veklury (remdesivir)\nfor the treatment of\nCOVID-19\u2014the science of safety and effectiveness. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness."}, {"Citation": "Gottlieb R. L.; Vaca C. E.; Paredes R.; Mera J.; Webb B. J.; Perez G.; Oguchi G.; Ryan P.; Nielsen B. U.; Brown M.; et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N. Engl. J. Med. 2022, 386, 305\u2013315. 10.1056/NEJMoa2116846.", "ArticleIdList": ["10.1056/NEJMoa2116846", "PMC8757570", "34937145"]}, {"Citation": "EUA 046 Gilead Remdesivir LOA Outpatients. U.S. Food and Drug Administration. https://www.fda.gov/media/137564/download."}, {"Citation": "Paymode D. J.; Cardoso F. S. P.; Agrawal T.; Tomlin J. W.; Cook D. W.; Burns J. M.; Stringham R. W.; Sieber J. D.; Gupton B. F.; Snead D. R. Expanding Access to Remdesivir via an Improved Pyrrolotriazine Synthesis: Supply Centered Synthesis. Org. Lett. 2020, 22, 7656\u20137661. 10.1021/acs.orglett.0c02848.", "ArticleIdList": ["10.1021/acs.orglett.0c02848", "PMC7536717", "32931286"]}, {"Citation": "Xie Y.; Hu T.; Zhang Y.; Wei D.; Zheng W.; Zhu F.; Tian G.; Aisa H. A.; Shen J. Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate. J. Org. Chem. 2021, 86, 5065\u20135072. 10.1021/acs.joc.0c02986.", "ArticleIdList": ["10.1021/acs.joc.0c02986", "33733767"]}, {"Citation": "Von Keutz T.; Williams J. D.; Kappe C. O. Flash Chemistry Approach to Organometallic C-Glycosylation for the Synthesis of Remdesivir. Org. Process Res. Dev. 2021, 25, 1015\u20131021. 10.1021/acs.oprd.1c00024.", "ArticleIdList": ["10.1021/acs.oprd.1c00024"]}, {"Citation": "Vieira T.; Stevens A. C.; Chtchemelinine A.; Gao D.; Badalov P.; Heumann L. Development of a Large-Scale Cyanation Process Using Continuous Flow Chemistry En Route to the Synthesis of Remdesivir. Org. Process Res. Dev. 2020, 24, 2113\u20132121. 10.1021/acs.oprd.0c00172.", "ArticleIdList": ["10.1021/acs.oprd.0c00172"]}, {"Citation": "Xue F.; Zhou X.; Zhou R.; Zhou X.; Xiao D.; Gu E.; Guo X.; Xiang J.; Wang K.; Yang L.; et al. Improvement of the C-glycosylation Step for the Synthesis of Remdesivir. Org. Process Res. Dev. 2020, 24, 1772\u20131777. 10.1021/acs.oprd.0c00310.", "ArticleIdList": ["10.1021/acs.oprd.0c00310"]}, {"Citation": "Kumar Palli K.; Ghosh P.; Krishna Avula S.; Sridhara Shanmukha Rao B.; Patil A. D.; Ghosh S.; Sudhakar G.; Raji Reddy C.; Mainkar P. S.; Chandrasekhar S. Total synthesis of remdesivir. Tetrahedron Lett. 2022, 88, 153590.10.1016/j.tetlet.2021.153590.", "ArticleIdList": ["10.1016/j.tetlet.2021.153590", "PMC8656175", "34908617"]}, {"Citation": "Warren T. K.; Jordan R.; Lo M. K.; Ray A. S.; Mackman R. L.; Soloveva V.; Siegel D.; Perron M.; Bannister R.; Hui H. C.; et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016, 531, 381\u2013385. 10.1038/nature17180.", "ArticleIdList": ["10.1038/nature17180", "PMC5551389", "26934220"]}, {"Citation": "Wang M.; Zhang L.; Huo X.; Zhang Z.; Yuan Q.; Li P.; Chen J.; Zou Y.; Wu Z.; Zhang W. Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir. Angew. Chem., Int. Ed. Engl. 2020, 59, 20814\u201320819. 10.1002/anie.202011527.", "ArticleIdList": ["10.1002/anie.202011527", "32870563"]}, {"Citation": "Gannedi V.; Villuri B. K.; Reddy S. N.; Ku C. C.; Wong C. H.; Hung S. C. Practical Remdesivir Synthesis through One-Pot Organocatalyzed Asymmetric (S)-P-Phosphoramidation. J. Org. Chem. 2021, 86, 4977\u20134985. 10.1021/acs.joc.0c02888.", "ArticleIdList": ["10.1021/acs.joc.0c02888", "33634692"]}, {"Citation": "Ross B. S.; Ganapati Reddy P.; Zhang H.-R.; Rachakonda S.; Sofia M. J. Synthesis of diastereomerically pure nucleotide phosphoramidates. J. Org. Chem. 2011, 76, 8311\u20138319. 10.1021/jo201492m.", "ArticleIdList": ["10.1021/jo201492m", "21916475"]}, {"Citation": "Chun B. K.; Clarke M. O.; Doerffler E.; Hui H. C.; Jordan R.; Mackman R. L.; Ray A. S.; Siegel D.. Methods for Treating Filoviridae Virus Infections. WO2016069826, 2016."}, {"Citation": "Hu T.; Xie Y.; Zhu F.; Gong X.; Liu Y.; Xue H.; Aisa H. A.; Shen J. One-Pot\u201d Synthesis of Molnupiravir from Cytidine. Org. Process Res. Dev. 2022, 26, 358\u2013364. 10.1021/acs.oprd.1c00419.", "ArticleIdList": ["10.1021/acs.oprd.1c00419"]}, {"Citation": "Hu T.; Xie Y.; Liu Y.; Xue H.; Zhu F. A.; Aisa H.; Shen J.. A Convenient and Cost Efficient Route Suitable for \u201cOne-Pot\u201d Synthesis of Molnupiravir.ChemRxiv, 2021.10.26434/chemrxiv.14208206.v1", "ArticleIdList": ["10.26434/chemrxiv.14208206.v1"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "8", "Day": "15", "Hour": "3", "Minute": "52"}, {"Year": "2022", "Month": "8", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "16", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "7", "Day": "27"}], "PublicationStatus": "epublish", "ArticleIdList": ["35967033", "PMC9366944", "10.1021/acsomega.2c02835"]}}], "PubmedBookArticle": []}